26U.F Curatis Holding AG

Healthcare Drug Manufacturers - Specialty & Generic Frankfurt Exchange
17.90 EUR
Close of Nov 11, 2026
11.70 28.60
Market cap
EUR 95.1M
P/E
-
P/B
1.75x
ROE
-3.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 26U.F undervalued?

Graham number

The Graham number of Curatis Holding AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Curatis Holding AG fundamental analysis

No fundamental analysis for Curatis Holding AG yet.

Curatis Holding AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Curatis Holding AG

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnosti…

Full company profile